Vanguard Capital Management’s Iovance Biotherapeutics IOVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$273M Buy
18,396,706
+192,458
+1% +$1.38M 0.01% 916
2026
Q2
$75.7M Buy
18,204,248
+1,586,511
+10% +$6.03M ﹤0.01% 1710
2026
Q1
$58.3M Buy
+16,617,737
New +$53.2M ﹤0.01% 1784

Other funds holding IOVA

Vanguard Capital Management's IOVA Position: Q3 2026 in Review

Vanguard Capital Management increased its Iovance Biotherapeutics (IOVA) stake by 1.1% in Q3 2026, buying an estimated $1.38M and bringing the position to 18,396,706 shares worth $273M. The position accounts for 0.01% of the portfolio, ranked #916.

Vanguard Capital Management first reported a position in IOVA in Q1 2026 and has held it in 3 quarters since. 334 funds tracked by Wall St. Rank hold IOVA as of Q3 2026.

  • Vanguard Capital Management held 18,396,706 shares of Iovance Biotherapeutics worth $273M as of Q3 2026.
  • Vanguard Capital Management bought 192,458 Iovance Biotherapeutics shares in Q3 2026, an estimated $1.38M.
  • Iovance Biotherapeutics made up 0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #916 holding.
  • Vanguard Capital Management first reported a position in Iovance Biotherapeutics in Q1 2026 and has held it in 3 quarters since.
  • 334 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.